An international, phase III study evaluating "efficacy and safety of retifanlimab in combination with standard carboplatin/paclitaxel in patients with inoperable locally advanced or metastatic squamous cell anal cancer" not receiving previous systemic chemotherapy was published in a recent issue of The Lancet. According to findings from the study, 14% of anal cancers are metastatic at diagnosis, 40% of patients with localized squamous cell anal cancer will progress after initial chemoradiation, and patents with distant metastasis have a 36% relative survival rate over a 5-year period.
To read more about this study, click here.
Sources mentioned:
- Rao S, Samalin-Scalzi E, Evesque L, et al. for the POD1UM-303/InterAACT-2 study investigators. Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial . The Lancet 2025;405(10495):P2144-2152.
- Martinelli E, Martini G. First-line immunotherapy combination in squamous cell anal carcinoma: hope in a neglected disease . The Lancet 2025;405(10495):P2106-2107.
No comments:
Post a Comment